RenovoRx Inc RNXT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $0.88
- Day Range
- $0.85–0.92
- 52-Week Range
- $0.70–1.45
- Bid/Ask
- $0.82 / $0.92
- Shares Outstanding
- 45.10M
- Market Cap
- $39.02M
- Volume/Avg
- 112,223 / 277,745
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 21.50
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 17
- Website
- https://www.renovorx.com
Valuation
|
Metric
|
RNXT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.46 |
Price/Sales | 21.50 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RNXT
|
|---|---|
Quick Ratio | 6.58 |
Current Ratio | 7.15 |
Interest Coverage | — |
Quick Ratio
RNXT
Profitability
|
Metric
|
RNXT
|
|---|---|
Return on Assets (Normalized) | −89.06% |
Return on Equity (Normalized) | −115.40% |
Return on Invested Capital (Normalized) | −116.35% |
Return on Assets
RNXT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|>bygF$< | LOCK|C@@ZM | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Bl#!&s? | LOCK|?H!SL | $71B | |||
| argenx SE ADR
ARGX
| LOCK|RYmQt% | LOCK|GX% | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<F%QTHV | LOCK|m@R | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|p!>?FG | LOCK|P&q$ | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|z#mgYghG | LOCK|&Z&H! | $26B | |||
| Moderna Inc
MRNA
| LOCK|p<cbTjc | LOCK|CJ | $25B | |||
| Incyte Corp
INCY
| LOCK|!#<<&$P | LOCK|yk | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|G^&&Y# | LOCK|fX | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|##S@R? | LOCK|X< | $16B |
United States